Vis enkel innførsel

dc.contributor.authorZykova, Svetlana
dc.contributor.authorBalandina, K
dc.contributor.authorVorokhobina, NV
dc.contributor.authorKuznetsova, A
dc.contributor.authorEngstad, R
dc.contributor.authorZykova, TA
dc.date.accessioned2015-03-11T07:15:55Z
dc.date.available2015-03-11T07:15:55Z
dc.date.issued2014
dc.identifier.citationJournal of Diabetes Investigation 5(2014) nr. 4 s. 392-399en_US
dc.identifier.cristinIDFRIDAID 1130805
dc.identifier.doi10.1111/jdi.12165
dc.identifier.issn2040-1116
dc.identifier.urihttps://hdl.handle.net/10037/7391
dc.identifier.urnURN:NBN:no-uit_munin_6981
dc.language.isoengen_US
dc.publisherWiley Open Accessen_US
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Generell indremedisin: 770en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::General internal medicine: 770en_US
dc.titleMacrophage stimulating agent soluble yeast β-1,3/1,6-glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo-controlled phase II studyen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel